RAUL RAMIREZ: Open Payments
NPI 1053459750 · KYLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$393 in 22 payments from 12 companies in 2025. Trend: 2023 $17 · 2024 $54 · 2025 $393
Food & beverage: $393
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 10 | $171 |
| Novo Nordisk Inc | 2 | $49 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $23 |
| Biogen, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Abbott Laboratories | 1 | $17 |
| Amgen Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
Products named: MOUNJARO, ZEPBOUND, KISUNLA, Ozempic, ISTURISA, LEQEMBI, VOQUEZNA, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
